Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.FREQ · Entity 6388 | Chief Manufacturing Officer | January 26, 2023 | January 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date January 26, 2023 · Filed January 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 105,000 |
Reported balance
After 2023-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-26 · Grant · Acquired 105,000 · Balance 105,000 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2023 Filed Jan 27, 2023 21:38 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002457 · form4.xml · derivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. F2 · derivative.expiration_date: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 90,000 | Not disclosed Strike: $38.99 | Not disclosed |
DisclosureSEC source: 0001127602-22-021369 · form4.xml · derivative · entry 2 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2031-01-28 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on January 19, 2022, and in equal monthly installments on the same day of each month thereafter and will be fully vested and exercisable on January 19, 2025. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 90,000 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021369 · form4.xml · derivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-28 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on January 19, 2022, and in equal monthly installments on the same day of each month thereafter and will be fully vested and exercisable on January 19, 2025. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 20:50 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 6,569 | $1.52 | $9,984.88 |
DisclosureSEC source: 0001127602-22-019049 · form4.xml · nonDerivative · entry 2 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,340 F3 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.49 to $1.56. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:50 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019049 · form4.xml · derivative · entry 3 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:50 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019049 · form4.xml · nonDerivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 4638 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2022. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:34 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,584 | $3.53 | $5,597.86 |
DisclosureSEC source: 0001127602-22-006314 · form4.xml · nonDerivative · entry 2 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,771 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.40 to $3.73. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:34 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,411 | $3.87 | $5,463.39 |
DisclosureSEC source: 0001127602-22-006314 · form4.xml · nonDerivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,355 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.80 to $3.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:10 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005747 · form4.xml · derivative · entry 3 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F5 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:10 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,303 | $4.20 | $5,467.39 |
DisclosureSEC source: 0001127602-22-005747 · form4.xml · nonDerivative · entry 2 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,766 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.00 to $4.48. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:10 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,233 | $4.43 | $5,460.96 |
DisclosureSEC source: 0001127602-22-005747 · form4.xml · nonDerivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,069 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.29 to $4.54. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 22:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,261 | $4.33 | $5,461.39 |
DisclosureSEC source: 0001127602-22-005334 · form4.xml · nonDerivative · entry 2 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,302 F3 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.28 to $4.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005334 · form4.xml · derivative · entry 3 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005334 · form4.xml · nonDerivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 2063 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2021. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | PurchaseCommon Stock | 10,000 | $8.85 | $88,500.00 |
DisclosureSEC source: 0001127602-21-017370 · form4.xml · nonDerivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 20:23 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014293 · form4.xml · derivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 21:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 90,000 | $0.00 Strike: $38.99 | $0.00 |
DisclosureSEC source: 0001127602-21-003255 · form4.xml · derivative · entry 1 McCubbin Quentin · CIK 0001842009 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on January 19, 2022, and in equal monthly installments on the same day of each month thereafter and will be fully vested and exercisable on January 19, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.